Consensus Alnylam Pharmaceuticals, Inc. BOERSE MUENCHEN

Equities

DUL

US02043Q1076

Real-time BOERSE MUENCHEN Other stock markets 11:13:21 28/06/2024 BST			5-day change	1st Jan Change
229.4 ^EUR	-0.52%		+57.46%	+30.28%

06-27	Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	MT
06-27	RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating	MT

Evolution of the average Target Price on Alnylam Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

cc8b8.5NnVuLKgWMInZjMYdbER7fwBu4yd2aWM-pKmF6DTsOQ.romg1MWTdfVvCH9tR8B8gJ4s6aHam-zUnafne-yj-tWwqOft6tAsqVIkXA~1b7a9e02e6dfcf113981870f3bdb1bbe

Analyst Recommendations on Alnylam Pharmaceuticals, Inc.

Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	06-27	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating	06-27	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing	06-26	MT
TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating	06-25	MT
Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating	06-25	MT
Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating	06-25	MT
Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating	06-25	MT
Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating	06-25	MT
Chardan Raises Price Target on Alnylam Pharmaceuticals to $265 From $225, Keeps Buy Rating	06-25	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating	06-25	MT
ANALYST RECOMMENDATIONS : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	06-25
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing	06-03	MT
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating	05-07	MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	04-08
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	02-26
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	02-21
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating	02-16	MT
Goldman Sachs Downgrades Alnylam Pharmaceuticals to Neutral From Buy, Cuts Price Target to $173 From $230	02-16	MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...	02-16
Wolfe Research Initiates Coverage on Alnylam Pharmaceuticals With Peer Perform Rating	02-15	MT
Morgan Stanley Adjusts Alnylam Pharmaceuticals' PT to $176 From $184, Keeps Equalweight Rating	02-13	MT
JPMorgan Adjusts Alnylam Pharmaceuticals' Price Target to $170 From $150, Keeps Neutral Rating	02-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

247 USD

Average target price

247.2 USD

Spread / Average Target

+0.07%

High Price Target

400 USD

Spread / Highest target

+61.94%

Low Price Target

150 USD

Spread / Lowest Target

-39.27%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Alnylam Pharmaceuticals, Inc.

HC Wainwright
Chardan Research
Goldman Sachs
Wolfe Research
Morgan Stanley
JPMorgan Chase
RBC Capital Markets
Wells Fargo Securities
UBS
Oppenheimer
Bernstein
Evercore ISI
TD Cowen
BMO Capital
Citigroup
Needham & Co.
Raymond James
Canaccord Genuity
EF Hutton
SVB Securities LLC
Piper Sandler
Berenberg Bank
Jefferies & Co.
Cantor Fitzgerald
Guggenheim
William Blair & Co.
SVB Leerink
Stifel Nicolaus
Chardan
Barclays
Cowen

Ratings for Alnylam Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar